Latest news

• AbbVie preps uterine fibroid filing after phase 3 win

  life. AbbVie says it is now planning to file its first applications for the drug in uterine fibroids in mid-2019. ... Uterine fibroids are non-cancerous tumours that form in the muscle walls of the uterus and affect between 20% and 80% of women by the

• FDA rejects Allergan’s uterine fibroid drug over safety concerns

  Allergan’s hopes of its investigational uterine fibroid drug hitting blockbuster status have taken a knock-back following a rejection on its marketing application by the US Food and Drug Administration ... He added: “Allergan continues to believe in

• AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod

  uterine fibroids are approved by regulators. ... Their relugolix candidate has positive mid-stage results in endometriosis-related pain, uterine fibroids, and prostate cancer, and is currently in phase III testing with some results due next year.

• AbbVie’s uterine fibroids drug aces second phase III trial

  or in early 2019, setting up a possible launch in uterine fibroids in 2020. ... Elagolix isn’t the only drug aiming to provide an oral therapy for uterine fibroids.

• MHRA suspends new prescriptions of fibroid drug Esmya

  In December, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) started a review of the treatment for abnormal bleeding in women with uterine fibroids after four cases of serious liver injury - ... Esmya (ulipristal acetate) is a selective